Clinical Trial: A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07622186) titled 'A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)' on May 26.

Brief Summary: This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 Combination Therapy in participants with Non-Small Cell Lung Cancer (NSCLC).

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: Non-Small Cell Lung Cancer

Intervention: DRUG: SKB571 for injection

Intravenous(IV) infusion(Q3W)

DRUG: Osimertinib

orally once daily

DRUG: Furmonertinib

orally once daily

DRUG: carboplatin

Intravenous(...